FCF Earns a “Give with Confidence” Rating

FCF is proud to announce that its strong financial health and ongoing accountability and transparency have earned a 100/100 rating from Charity Navigator’s new Encompass Rating System. This score designates FCF as an official “Give with Confidence” charity, indicating that our organization is using its donations effectively based on Charity Navigator’s criteria. Charity Navigator is …

Read moreFCF Earns a “Give with Confidence” Rating

FCF/CRI Fellowship Winner Announced

Albert Einstein College of Medicine’s Dr. Francesco Juan Martinez Navarro has been awarded this prestigious three-year fibrolamellar (FLC)  research fellowship. This is the fifth Cancer Research Institute (CRI) fellowship that FCF has funded in the past five years.  Read about Francisco’s important focus to further advance FLC discoveries.

Cornell University Study Identifies Critical Genes Involved in FLC

In this study published in Cell Reports, FCF-funded researcher Praveen Sethupathy and his team at Cornell University have leveraged a novel genomics technology to uncover therapeutic vulnerabilities in fibrolamellar carcinoma. Collaborators on the study include FCF-funded John Scott and F. Donelson Smith at the University of Washington. The lead author is Tim Dinh, who recently …

Read moreCornell University Study Identifies Critical Genes Involved in FLC

A Red Letter Day for FLC

April 21st was a red letter day for the fibrolamellar community. A patient at the Sidney Kimmel Comprehensive Cancer Center of Johns Hopkins University, Baltimore, MD received the initial treatment of the first experimental therapy aimed to directly target the primary molecular cause of fibrolamellar carcinoma (FLC)…

Read more

Opening of FLC Peptide Vaccine Clinical Trial

A new clinical trial of an immune therapy for fibrolamellar carcinoma (FLC) is now recruiting subjects at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University in Baltimore, MD. The study asks if individuals can mount an effective immune response against FLC by specifically targeting the unique chimeric protein …

Read more